Expert Interview
A Second View: Exploring the potential impact of the FDA's approval of inavolisib, palbociclib, and fulvestrant for treating endocrine-resistant, PIK3CA-mutated, HR-positive advanced breast cancer on future oncology patient care.
Ticker(s): RHHBYInstitution: University of Pittsburgh Medical Center
- Assistant Professor in the Department of Medicine at the University of Pittsburgh.
- Mages approximately 15 patients monthly with advanced breast cancer.
- Clinical and translational researcher focusing on improving treatments for patients with breast cancer through complementing clinical care with robust clinical investigation and translational research.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
